Some good luck and transition in its portfolio has Actelion ahead of analysts' estimates and projecting a strong year for its PAH franchise as it launches its latest product. A delay in generics for its old blockbuster is giving its two newest products time to find their footing.
Europe's largest biotech announced fourth quarter and full year earnings Feb. 9 that turned out to be a pleasant surprise...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
